Prasad Pallavi, Sharma Sourabh, Mohanasundaram Subashri, Agarwal Anupam, Verma Himanshu
Department of Nephrology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, Delhi, India.
Department of Nephrology, Prashanth Hospital, Chennai 600042, Tamil Nādu, India.
World J Transplant. 2024 Sep 18;14(3):96225. doi: 10.5500/wjt.v14.i3.96225.
Tuberculosis (TB) is the leading cause of infectious mortality and morbidity in the world, second only to coronavirus disease 2019. Patients with chronic kidney disease and kidney transplant recipients are at a higher risk of developing TB than the general population. Active TB is difficult to diagnose in this population due to close mimics. All transplant candidates should be screened for latent TB infection and given TB prophylaxis. Patients who develop active TB pre- or post-transplantation should receive multidrug combination therapy of antitubercular therapy for the recommended duration with optimal dose modification as per glomerular filtration rate.
结核病（TB）是全球传染性死亡和发病的主要原因，仅次于2019冠状病毒病。慢性肾脏病患者和肾移植受者比普通人群患结核病的风险更高。由于临床表现相似，该人群中的活动性结核病难以诊断。所有移植候选者都应进行潜伏性结核感染筛查并给予结核病预防治疗。移植前或移植后发生活动性结核病的患者应接受抗结核治疗的多药联合治疗，疗程为推荐疗程，并根据肾小球滤过率进行最佳剂量调整。
